TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Potassium Citrate in the Treatment of Postmenopausal Osteopenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Postmenopausal women, more than 5 years post menopause~* Osteopenia (T-score \< -1 and \> -2.5)~* Low risk of fracture (FRAX: \< 20 major osteoporotic; \< 3 hip fracture)~Exclusion Criteria:~* Hyperkalemia~* Renal insufficiency~* Nephrolithiasis~* Use of potassium sparing diuretics~* Use of potassium supplements~* Use of therapies influencing bone metabolism (e.g. corticosteroids, thiazide diuretics, aromatase inhibitors, estrogens)~* Use of protonic pump inhibitors~* Current or recent use of bisphosphonates (stopped less than three years prior to the start of the study)~* Gastrointestinal disorders that hamper nutrient absorption;~* Mental or psychiatric disorders that preclude the possibility of correctly adhering to the protocol

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment group (Type: EXPERIMENTAL): Potassium citrate Calcium carbonate Vitamin D3
- Control group, Placebo (Type: PLACEBO_COMPARATOR): Placebo (Excipients) Calcium carbonate Vitamin D3

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Linagliptin 2.5 mg Twice Daily Versus 5 mg Once Daily as add-on Therapy to Twice Daily Metformin in Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion criteria~1. Diagnosis of type 2 diabetes mellitus.~2. Current treatment with metformin alone (\>/= 1500 mg or maximally tolerated dose) or metformin plus 1 other antidiabetic drug. Metformin must be administered in twice daily dosing regimen. Patients taking metformin three times daily can be included if posology is switched to twice daily and total daily dose is maintained.~3. Glycosylated haemoglobin (HbA1c) is between 7.0% - 10.0%.~4. Body Mass Index (BMI) \</=45 kg/m2.~Exclusion criteria~1. Treatment with extended release metformin.~2. Uncontrolled hyperglycaemia (fasting plasma glucose \> 240 mg/dL or 13.3 mmol/L).~3. Myocardial infarction (MI), stroke or transient ischaemic attack (TIA) within 6 months prior to informed consent.~4. Impaired hepatic or renal function, or gastric bypass surgery.~5. Treatment with glitazones, glucagon like peptide-1 (GLP-1) analogues/mimetics, antiobesity agents, or insulin within 3 months of informed consent.~6. Current treatment with systemic steroids or change in dosage of thyroid hormones.~7. Alcohol or drug abuse within 3 months of informed consent.~8. Participation in another trial with investigational drug within 2 months prior to informed consent.~9. Pre-menopausal women who are nursing, pregnant or not practicing an acceptable method of birth control.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- linagliptin low dose (Type: EXPERIMENTAL): linagliptin low dose twice daily
- placebo (Type: PLACEBO_COMPARATOR): placebo matching linagliptin
- linagliptin medium dose (Type: EXPERIMENTAL): linagliptin medium dose once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Stroke Hyperglycemia Insulin Network Effort (SHINE) Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age 18 years or older~2. Clinical diagnosis of ischemic stroke defined as acute neurological deficit occurring in one or more cerebral vascular territories. Neuroimaging must be done to exclude intracranial hemorrhage (ICH).~3. Randomization must be within 12 hours after stroke symptom onset and treatment is recommended, but not required, to begin within 3 hours after hospital arrival. If time of symptom onset is unclear or patient is awakening with stroke symptoms, the time of onset will be the time the patient was last known to be normal.~4. Known history of type 2 diabetes mellitus and glucose \>110 mg/dL OR admission blood glucose ≥150 mg/dL in those w/o known diabetes mellitus~5. Baseline NIHSS score of 3-22~6. Pre-stroke modified Rankin Scale score = 0 for patients with an NIHSS score of 3-7. Pre-stroke modified Rankin Scale score = 0 or 1 for patients with an NIHSS score of 8-22.~7. Able to provide a valid informed consent to be in the study (self or their authorized legally accepted representative). The approved consent form must be signed and dated in accordance with federal and institutional guidelines.~Exclusion Criteria:~1. Known history of type 1 diabetes mellitus~2. Substantial pre-existing neurological or psychiatric illness that would confound the neurological assessment or other outcome assessment~3. Having received experimental therapy for the enrollment stroke. IV tPA (up to 4.5 hrs) or IA tPA are allowed as are IA therapies including use of FDA cleared devices. Non FDA cleared devices are considered experimental and are excluded.~4. Pregnant or breast-feeding at the time of study entry~5. Other serious conditions that make the patient unlikely to survive 90 days~6. Inability to follow the protocol or return for the 90 day follow up~7. Renal dialysis (including hemo or peritoneal dialysis)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- IV insulin drip with target glucose 80 mg/dL - 130 mg/dL (Type: EXPERIMENTAL): The intervention arm will have a targeted glucose concentration of 80-130 mg/dL. IV insulin drip will be titrated to keep glucose concentration in this range.
- Sub Q insulin to keep glucose less than 180 mg/dL (Type: ACTIVE_COMPARATOR): This standard care arm will get sub q insulin sliding scale to keep glucose concentration less than 180 mg/dL

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study Evaluating the Efficacy and Safety of ABP 959 Compared With Eculizumab in Adult Participants With PNH

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men and women ≥ 18 years of age.~* Historical diagnosis of PNH.~* Administration of eculizumab for ≥ 6 months and currently receiving 900 mg of eculizumab.~* Hemoglobin ≥ 9.0 g/dL for at least 6 weeks before randomization.~* Lactate dehydrogenase \< 1.5 × the upper limit of normal at screening.~* Platelet count ≥ 50 × 10\^9/L.~* Absolute neutrophil count (ANC) ≥ 0.5 x 10\^9/L (500/μL).~* Participants must be vaccinated against Neisseria meningitidis.~* Participants must sign an IRB/IEC-approved ICF before participation in any procedures.~Exclusion Criteria:~* Known or suspected hereditary complement deficiency.~* Clinically significant cardiovascular disease (including myocardial infarction, unstable angina, symptomatic congestive heart failure \[New York Heart Association ≥ Class III\], serious uncontrolled cardiac arrhythmia), peripheral vascular disease, cerebrovascular accident, or transient ischemic attack in the previous 6 months.~* Evidence of acute thrombosis (liver Doppler ultrasound of hepatic and portal veins).~* Known to be positive for human immunodeficiency virus.~* Woman who is pregnant or breastfeeding.~* Participant is currently enrolled in or has not yet completed at least 30 days since ending other investigational device or drug study(s), or participant is receiving other investigational agent(s).~* Participant has known sensitivity to any of the products to be administered during the study, including mammalian cell-derived drug products.~* History of meningococcal infection.~* Presence or suspicion of active bacterial infection, or recurrent bacterial infection.~* History of bone marrow transplantation.~* Red blood cell transfusion required within 12 weeks before randomization.~* Participant experienced ≥ 2 breakthrough events, (ie, signs and symptoms of intravascular hemolysis, that require dose and/or schedule adjustments of eculizumab) in the previous 12 months before screening.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- T (ABP 959) / R (eculizumab) (Type: OTHER): ABP 959 for 52 weeks in Period 1 followed by eculizumab for 26 weeks in Period 2
- R (eculizumab) / T (ABP 959) (Type: OTHER): Eculizumab for 52 weeks in Period 1 followed by ABP 959 for 26 weeks in Period 2

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Midodrine for Improving Hemodynamics After Spinal Anesthesia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* • American Society of Anesthesiologists (ASA) status: 1 or 2 .~  * Orthopedic surgery on the lower extremities~Exclusion Criteria:~* • Pheochromocytoma. .Throtoxicosis. .Structural heart disease.~  * Baseline blood pressure more than 140/90 .Acute kidney failure.~ * Any contraindications to spinal anesthesia such as local infection and coagulopathy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Group A (midodrine group) (Type: ACTIVE_COMPARATOR): Midodrine will be given orally with small sips of water one hour before arrival in the operation room before spinal anesthesia
- Group B (placebo group): (Type: PLACEBO_COMPARATOR): Inert tablet containing sugar (placebo) will be given orally with small sips of water one hour before arrival in the operation room before spinal anesthesia

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Different Doses of VAC52416 (ExPEC10V) in Japanese Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Participant must be Japanese as determined by participant's verbal report~* Must be healthy or medically stable, in the investigator's clinical judgment, as confirmed by medical history, physical examination, vital signs, 12-lead electrocardiogram (ECG), and clinical laboratory tests performed at the screening visit~* Willing and able to adhere to the lifestyle restrictions~* Agrees not to donate blood until 12 weeks after receiving the study intervention~* Must be willing to provide verifiable identification, has means to be contacted, and to contact the investigator during the study~Exclusion Criteria:~* Clinically significant illness (this does not include minor illnesses such as diarrhea or mild upper respiratory tract infection) or temperature greater than or equal to (\>=) 38.0 degree Celsius (100.4 degree Fahrenheit ) within 24 hours prior to the administration of study intervention; enrollment at a later date is permitted (provided the screening window of 28 days is respected)~* History of malignancy within 5 years before screening (exceptions are squamous and basal cell carcinomas of the skin and carcinoma in situ of the cervix, or malignancy, which is considered cured with minimal risk of recurrence)~* Known allergies, hypersensitivity, or intolerance to ExPEC10V or its excipients~* Known allergy or history of anaphylaxis or other serious adverse reactions to vaccines or vaccine excipients~* Contraindication to Intramuscular (IM) injections and blood draws example, bleeding disorders

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: 85 Years
- Healthy Volunteers: t

Study Arms:
- Medium-dose ExPEC10V or Placebo: Group 1 (Type: EXPERIMENTAL): Participants will be randomized to receive a single intramuscular (IM) injection of medium dose of ExPEC10V or Placebo on Day 1.
- High-dose ExPEC10V or Placebo: Group 2 (Type: EXPERIMENTAL): Participants will be randomized to receive a single IM injection of high dose (based on safety assessment through Day 15 postvaccination of medium dose) of ExPEC10V or Placebo on Day 1.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison Between Propofol-remifentanil Total Intravenous Anesthesia and Desflurane-remifentanil Balanced Anesthesia With Regard to Post-anesthetic Functional Recovery Measured With QoR-40

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* patients who are undergoing thyroid operation belong to ASA class 1 or 2~Exclusion Criteria:~* patients who are belongs to ASA class 3 or more,~* patients who have underlying complicated cardiovascular or psychological disease.

- Gender: FEMALE
- Minimum Age: 20 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Desflurane group (Type: EXPERIMENTAL): None
- TIVA(total intravenous anesthesia) group (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Global REsponsE During iNFusIon of a gEl With LevoDopa/Carbidopa

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Participants already on treatment with DUODOPA (having already concluded the naso-intestinal treatment phase) according to the local DUODOPA product label and to routine clinical care for advanced PD patients~* Participants with available data on DUODOPA treatment, on previous PD conventional treatments and with at least one of the scales/questionnaires under study already collected on the participant's clinical chart~* Participant or legal representative has given written informed consent~* Non-professional caregiver (relative or familiar who give daily assistance to the patient) has given his/her written consent~Exclusion Criteria:~• History or presence of any condition that might interfere with the long-term continuation of the duodenal infusion of DUODOPA

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Participants with Parkinson's disease (Type: None): Participants with advanced levodopa-responsive Parkinson's disease and severe motor fluctuations and hyper-/dyskinesia who were prescribed and treated in accordance with the local levodopa/carbidopa intestinal gel product label

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Selecting Treatment With Desmopressin or Alarm to Children With Enuresis Based on Home Recordings.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Age 6-14 years.~* Three or more wet nights per week regarding the home registrations.~Exclusion Criteria:~* Ongoing constipation and/or faecal incontinence.~* Daytime symptoms such as urgency, frequency or incontinence.~* Recurrent urinary tract infections.~* Anamnestic, clinical or laboratory findings that can be related to diseases or conditions that might affect the parameters investigated.~* Neurological and/or known clinically significant anatomical abnormalities of the urinary tract.~* Former operations in the urinary tract.~* Prior or ongoing treatment with alarm, desmopressin or anticholinergics.~* Ongoing medication that may interfere with the parameters tested.~* Pregnant or lactating girl.~* Contra-indications for the use of desmopressin: habitual or psychogenic polydipsia, use of diuretics, renal insufficiency, hyponatremia or SIADH.~* Hypersensitivity / allergy to substances in the tablets.

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 14 Years
- Healthy Volunteers: f

Study Arms:
- Treatment without evaluating the home recordings, medicin. (Type: EXPERIMENTAL): Children will receive desmopressin without evaluating the home recordings.
- Treatment without evaluating the home recordings, alarm. (Type: EXPERIMENTAL): Children will receive conditional alarm without evaluating the home recordings.
- Treatment based on home recordings, polyuria. (Type: ACTIVE_COMPARATOR): Children with polyuria based on the home recordings will receive desmopressin.
- Treatment based on home recordings, reduced bladder capacity. (Type: ACTIVE_COMPARATOR): Children with reduced bladder capacity based on the home recordings will receive the conditional alarm.
- Treatment based on home recordings, both. (Type: ACTIVE_COMPARATOR): Children with polyuria and reduced bladder capacity based on the home recordings will receive desmopressin and the conditional alarm.
- Treatment based on home recordings, none. (Type: ACTIVE_COMPARATOR): Children with neither nocturnal polyuria nor reduced bladder capacity based on the home recordings will be randomized to either desmopressin or alarm treatment. If there is no effect of the treatment, the treatment can be switched.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Viagra in the Treatment of Primary Dysmenorrhea

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Primary dysmenorrhea at current visit, with a visual analogue scale (VAS) score of \>35; pain defined as moderate or severe on a categorical of none, mild, moderate, severe.~Exclusion Criteria:~* Secondary dysmenorrhea~* Any current medication~* Serious medical condition

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 35 Years
- Healthy Volunteers: t

Study Arms:
- Sildenafil Citrate (Type: EXPERIMENTAL): A single vaginal dose of Viagra 100 mg.
- Placebo (Type: PLACEBO_COMPARATOR): A single vaginal dose of placebo.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Differential Adrenoreceptor Mediated Tachyphylaxis and Upregulation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male of Female aged 18-65 years.~* Healthy volunteers with a negative history of seasonal or perennial nasal symptoms other than occasional common colds. Atopy will not preclude inclusion into the study as long as patients have no nasal symptoms.~* Current non-smokers (ex-smokers for greater than 6 months duration with a total smoking history of less than 5 pack-years will be eligible).~* PNIF \> 100L/min (best effort of 3) and reversibility with OXY 2 squirts in each nostril (20 min reading) \> 20 L/min.~* Ability to give a written informed consent.~* Ability and willingness to comply with the requirements of the protocol.~Exclusion Criteria:~* Recent respiratory tract/sinus infection within the last 2 months.~* Pregnancy, planned pregnancy or lactation.~* Known or suspected hypersensitivity to any of the IMP's.~* Concomitant use of medicines (prescribed, OTC or herbal) like alpha blockers that may interfere with the trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: EXPERIMENTAL): Prazosin 1mg challenge to block alpha 1 adrenoreceptors
- 2 (Type: PLACEBO_COMPARATOR): Placebo to Prazosin

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Long Term Follow up Study of Patients Who Have Completed the PEP005-016 or PEP005-025 Studies

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patient must have achieved complete clearance of AK lesions (lesion count = 0) at Day 57 in one of the following Peplin AK clinical studies: PEP005-016 or PEP005-025~* Patient has provided informed consent documented by signing the Informed Consent Form (ICF) prior to any study-related procedures~Exclusion Criteria:~* Concurrent participation in another research study which would involve the selected treatment area (except for any post-study follow-up visits for previous Peplin AK study)~* Early termination from study PEP005-016 or PEP005-025

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete